medigraphic.com
Colegio de Medicina Interna de México.

2011, Number 1

<< Back Next >>

Med Int Mex 2011; 27 (1)

Estudio metabólico de los familiares de pacientes con diabetes tipo 2

Lozada TAL, Fabian MG, Fernández PMR, García SMC

Language: Spanish
References: 25
Page: 5-10
PDF size: 366.81 Kb.


ABSTRACT

Background: In Mexico, cardiovascular diseases are the leading cause of mortality among adults, and the Metabolic Syndrome (MS) is considered a particularly important factor in the development of this type of disease and of type 2 diabetes (diabetes mellitus tipo 2). Thus, the aim of this study was to assess the prevalence of MS among relatives of diabetes mellitus tipo 2 patients treated at a tertiary care institution.
Patients and Methods: A transversal study of 72 relatives of patients diagnosed with diabetes mellitus tipo 2 who were selected randomly at the INER’s outpatient service. A standardized questionnaire was applied to obtain socioeconomic, anthropometric, clinical and laboratory information. The following criteria were taken into account in evaluating MS: those of the World Health Organization (WHO), the International Diabetes Federation (IDF), and the National Cholesterol Education Program (ATPIII).
Results: The mean age of the group was 47.1 years (±13.9). Of the 72 participants, 79% were women. A total of 78% of subjects were overweight or obese. The mean body mass index (BMI) was 29.2 (±6.55). The most frequently found MS components were as follows: general or abdominal obesity, hypertriglyceridemia and low HDL cholesterol. Depending upon the specific criteria applied the prevalence of MS in the sample as a whole ranged from 16 to 34%.
Conclusions: The relatives of the diabetes mellitus tipo 2 patients showed elevated frequencies of obesity and MS, indicating that this population is at a high risk for developing cardiovascular and metabolic diseases, including diabetes. Preventive programs should be developed for this group to control these risk factors.


REFERENCES

  1. World Health Organization. Diabetes. Disponible en: www.who. int/topics/diabetes_mellitus/en/ (consultado 18 junio de 2009)

  2. Dirección General de Epidemiología. Anuarios de morbilidad. Veinte principales causas de enfermedad a nivel nacional por grupo de edad. Población general. Disponible en: http://www. dgepi.salud.gob.mx/anuario/html/anuarios.html

  3. Sistema Nacional de Información en Salud. Diez principales causas de mortalidad en hombres y en mujeres 2007. Disponible en: http://www.sinais.salud.gob.mx/descargas/xls/diezprincausasmort2007_C. xls

  4. Kuri-Morales P, Emberson J, Alegre-Díaz J, et al. The prevalence of chronic diseases and major disease risk factors at different ages among 150,000 men and women living in Mexico City: cross-sectional analyses of a prospective study. BMC Public Health 2009;9:9.

  5. Olaiz Fernández G, Rivera Dommarco J, Shamah Levy T, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca: Instituto Nacional de Salud Pública, 2006.

  6. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-1757.

  7. Freeman MS, Mansfield MW, Barrett JH, Grant PJ. Heritability of features of the insulin resistance syndrome in a communitybased study of healthy families. Diabet Med 2002;19:994-999.

  8. Bouchard C, Perusse L. Genetics of causes and manifestations of the metabolic syndrome. In: Crepaldi G, Tiengo A, Manzato E (eds). Diabetes, obesity and hyperlipidemia: The plurimetabolic syndrome. Amsterdam: Elsevier Science, 1993;p:67-74.

  9. Meigs JB, D'Agostino RB, Wilson PWF, Copples LA, et al. Risk variable clustering in the insulin resistance syndrome: The Framingham offspring study. Diabetes 1997;46:1594-1600.

  10. Kannel WB. The Framingham Study: ITS 50-year legacy and future promise. J Atheroscler Thromb 2000;6:60-66.

  11. Isomaa B, Almgrem P, Tuomi T, et al. Cardiovascular morbility and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.

  12. Bueno H. Prevención y tratamiento de la cardiopatía isquémica en pacientes con diabetes mellitus. Puesta al día. Diabetes y enfermedades cardiovasculares 2002;55:975-986.

  13. Lohman T, Roche A, Martorell R. Anthropometric standardization reference manual. Champlaign, IL: Human Kinetics, 1988.

  14. Alberti FGMM, Zimmet PZ, for the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998;15:539-553.

  15. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol. JAMA 2001; 285:2486-2497.

  16. The International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. 2005. Disponible en: http://www.idf.org/webdata/docs/Metac_ syndrome_def.pdf. Consultado el 8 de junio de 2010.

  17. Calderín BR, Yáñez QM, Márquez PI, et ál. Síndrome metabólico en familiares de primer grado de pacientes con diabetes mellitus tipo 2. Rev Cubana Endocrinol [online]. 2005:16(3) Disponible en:

  18. Cuevas-Alvarez NA, Vela-Otero Y, Carrada-Bravo T. Identification of risk factors in relatives of type-2 diabetics. Rev Med Inst Mex Seguro Soc 2006; 44:313-320.

  19. Aguilar-Salinas CA, Mehta R, Rojas R, Gómez-Pérez FJ, Olaiz G, Rull JA. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues. Curr Diabetes Rev 2005;1:145-158.

  20. Pomara F, Russo G, Amato G, Gravante G. Familiar history and predictive risk factors to type 2 diabetes: a cross sectional study in young Sicilian subjects of both sexes. Panminerva Med 2005; 47:259-264.

  21. Valdez R. Detecting undiagnosed type 2 diabetes: family history as a risk factor and screening tool. J Diabetes Sci Technol 2009; 3:722-726.

  22. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28:2745-2749.

  23. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proponed definitions. Diabetes Care 2003; 26:575-581.

  24. Lorenzo C, Williams K, Gónzalez-Villalpando C, Harrner SM. The prevalence of the metabolic syndrome did not increase in Mexico City between 1990-92 and 1997-99 despite more central obesity. Diabetes Care 2005; 28:2480-2485.

  25. Aguilar-Salinas CA, Rojas R, Gonzalez-Villalpando C, et ál. Design and validation of a population-based definition of the metabolic syndrome. Diabetes Care 2006; 29:2420-2426.




2020     |     www.medigraphic.com